Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.

For patients with stage IV NSCLC and varying comorbidity burden, first-line treatment with pembrolizumab does not represent a cost-effective strategy compared to chemotherapy. Resources should be focused on collecting immunotherapy survival data for more representative NSCLC patient populations.